Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Adawi KamalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,487Price:$1.91
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Adawi KamalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9,297Price:$1.91
-
Feb 29, 2024 (filed on Mar 04, 2024)Insider Name:Aballi JohnOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:9,804Price:$1.91
-
Feb 20, 2024 (filed on Feb 22, 2024)Insider Name:Adawi KamalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:75,000Price:--
-
Feb 20, 2024 (filed on Feb 22, 2024)Insider Name:Aballi JohnOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:175,000Price:--
-
Feb 06, 2024 (filed on Feb 08, 2024)Insider Name:Adawi KamalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-6,738Price:$1.95
-
Oct 17, 2023 (filed on Oct 18, 2023)Insider Name:Aballi JohnOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-33,819Price:$1.75
-
Aug 31, 2023 (filed on Sep 06, 2023)Insider Name:Aballi JohnOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:9,803Price:$2.14
-
Jul 24, 2023 (filed on Jul 26, 2023)Insider Name:Kim PaulOwnership Type:Direct OwnershipSecurities:Stock Option(right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:15,000Price:--
-
Jun 15, 2023 (filed on Jun 20, 2023)Insider Name:Nova Tina SusanOwnership Type:Direct OwnershipSecurities:Stock Option(right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:13,500Price:--
Filings by filing date
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Adawi KamalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,487Price:$1.91
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Adawi KamalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9,297Price:$1.91
-
Feb 29, 2024 (filed on Mar 04, 2024)Insider Name:Aballi JohnOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:9,804Price:$1.91
-
Feb 20, 2024 (filed on Feb 22, 2024)Insider Name:Adawi KamalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:75,000Price:--
-
Feb 20, 2024 (filed on Feb 22, 2024)Insider Name:Aballi JohnOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:175,000Price:--
-
Feb 06, 2024 (filed on Feb 08, 2024)Insider Name:Adawi KamalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-6,738Price:$1.95
-
Oct 17, 2023 (filed on Oct 18, 2023)Insider Name:Aballi JohnOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-33,819Price:$1.75
-
Aug 31, 2023 (filed on Sep 06, 2023)Insider Name:Aballi JohnOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:9,803Price:$2.14
-
Jul 24, 2023 (filed on Jul 26, 2023)Insider Name:Kim PaulOwnership Type:Direct OwnershipSecurities:Stock Option(right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:15,000Price:--
-
Jun 15, 2023 (filed on Jun 20, 2023)Insider Name:Nova Tina SusanOwnership Type:Direct OwnershipSecurities:Stock Option(right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:13,500Price:--
News
Biz Brief
Sector: Healthcare | Industry: Healthcare Facilities & Services |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1261 Liberty Way Ste C VISTA CA 92081-8356 |
Tel: | N/A |
Website: | https://exagen.com |
IR: | See website |
Key People | ||
Tina Susan Nova Executive Chairperson of the Board | John Aballi President, Chief Executive Officer, Director | Kamal Adawi Chief Financial Officer, Corporate Secretary |
Business Overview |
Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results. |
Financial Overview |
For the fiscal year ended 31 December 2023, Exagen Inc revenues increased 15% to $52.5M. Net loss decreased 50% to $23.7M. Revenues reflect Client segment increase of 25% to $9.9M, Government segment increase of 2% to $18M. Lower net loss reflects Goodwill impairment decrease from $5.5M (expense) to $0K, Research and development expenses decrease of 50% to $4.6M (expense). |
Employees: | 174 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $8.19M as of Dec 31, 2023 |
Annual revenue (TTM): | $52.55M as of Dec 31, 2023 |
EBITDA (TTM): | -$20.67M as of Dec 31, 2023 |
Net annual income (TTM): | -$23.69M as of Dec 31, 2023 |
Free cash flow (TTM): | -$15.29M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 17,235,751 as of Mar 14, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |